Published in Hepatitis Weekly, January 9th, 2006
"Although combination therapy with interferon and ribavirin has improved the treatment for chronic HCV infection, the detailed anti-HCV effect of ribavirin in clinical concentrations remains uncertain," wrote T. Kato and colleagues, Tokyo Metropolitan Institute of Neuroscience.
"To detect the anti-HCV effect of ribavirin in lower concentrations, a sensitive and accurate assay system was developed using the reporter replicon system with an HCV genotype 2a subgenomic replicon (clone JFH-1) that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly